The beauty and personal care sector in 2025 embraced a more disciplined approach to capital deployment, prioritising strategic assets, innovation, and consolidation amid cautious market conditions, marking a significant transformation in industry funding and growth strategies.
If 2025 taught the beauty and personal care sector one lesson, it was that capital remains available but is being deployed with greater discipline. Across public markets, private equity and corpor...
Continue Reading This Article
Enjoy this article as well as all of our content, including reports, news, tips and more.
By registering or signing into your SRM Today account, you agree to SRM Today's Terms of Use and consent to the processing of your personal information as described in our Privacy Policy.
Large corporates led the recalibration. L’Oréal crystallised value and improved financial flexibility by selling a 2.3% stake in Sanofi for €3 billion in an off‑market block trade, a deal Sanofi said was part of its share‑buyback programme and that will see the repurchased shares cancelled by 29 April 2025. The transaction reduced L’Oréal’s holding to 7.2% of Sanofi’s share capital and 13.1% of voting rights, a move L’Oréal described as optimising its balance sheet following recent acquisitions while preserving its role as a significant Sanofi shareholder. At the same time, L’Oréal continued to channel capital into science and capacity, including a US$160 million innovation centre in New Jersey and wider investments across Mexico and China, underscoring the industry’s tilt toward durable, innovation‑led advantages.
Luxury groups pursued similar portfolio discipline. Kering completed the sale of The Mall Luxury Outlets to US REIT Simon for approximately €350 million, a divestment the company said would let it concentrate outlet distribution into a smaller number of exclusive venues. Later developments in the sector reinforced this refocusing: industry reporting and company announcements showed an intensifying move to concentrate on core fashion and high‑margin beauty licences. In a landmark strategic shift announced in 2025, L’Oréal and Kering unveiled an estimated €4 billion alliance that includes the acquisition of Creed and long‑term licences to develop beauty for several couture houses, a deal industry observers described as one of the most consequential capital partnerships in recent years and as evidence of consolidation at the luxury end of the market.
Debt markets remained a pragmatic source of funding as firms sought to shore up liquidity rather than fuel aggressive expansion. Major issuances and refinancings, by companies such as Procter & Gamble, Coty and Unilever, reflected an emphasis on balance‑sheet management. Retail and pharmacy groups also restructured capital: Macy’s and Walgreens Boots Alliance pursued note and loan transactions to support strategic deals and transformations, with Walgreens suspending its dividend to preserve cash during a take‑private process.
Private capital was selective but active. Private equity and strategic investors continued to back brands that demonstrated clear pathways to scale or category leadership: minority investments and growth rounds for premium and tech‑enabled brands illustrated a preference for businesses with demonstrable unit economics or defensible niches. L’Oréal’s corporate venture vehicle, BOLD, and other corporate investors remained engaged in early and growth rounds across regions from India to Korea, where national funds and local venture capital targeted K‑beauty startups amid geopolitical trade concerns.
Asia, and India in particular, was a magnet for investment. Several mid‑to‑late‑stage rounds in the region underscored the depth of consumer opportunity: Series C financings and strategic partnerships with Japanese and global cosmetics groups highlighted both cross‑border capital flows and the sector’s appetite for market share expansion in fast‑growing economies.
The market for initial public offerings was mixed. While some beauty tech and retail groups revived listing plans, other marquee IPO ambitions were paused or repriced as investor selectivity and valuation pressure persisted. Reporting through the year highlighted both renewed attempts to list and high‑profile postponements, reflecting a cautious appetite for new equity from public investors.
Venture capital remained robust where beauty intersected with technology and wellness. Funding flowed to medspa platforms, at‑home treatments, AI safety testing for ingredients and creator commerce models, signalling that investors prized businesses that combined category innovation with scalable, technology‑driven distribution.
Public policy and infrastructure investment provided further tailwinds. Large technology and financial services firms expanded digital and logistics capacity, while partnerships to digitise payments and support entrepreneurs in emerging markets illustrated how corporate and government initiatives can amplify commercial opportunities for beauty brands.
The product landscape also evolved alongside finance. Reporting by Le Monde highlighted an extraordinary surge in fragrances in 2025, some 6,000 new perfumes launched globally, as younger consumers and social media trends turned scent into a fast‑moving, collectible category. That boom helped fuel double‑digit growth for major fragrance players and underpinned new manufacturing investments, reinforcing why companies were willing to redeploy capital into production and premium brand extensions.
Taken together, the year showed funding in beauty was not contracting so much as maturing: capital favoured companies that could demonstrate disciplined portfolios, credible science and the infrastructure to scale sustainably. In that environment, the winners were those that balanced ambition with balance‑sheet strength, turning investor selectivity into a test of commercial durability rather than a brake on innovation.
Source: Noah Wire Services
Subscribe to Industry Updates
